AI Article Synopsis
- Neuroendocrine tumors (NETs) of the pancreas and midgut are very rare in children, and those with metastatic disease face low survival rates.
- Recent adult clinical trials indicate that adding peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE significantly improves disease control, achieving about 80% effectiveness with few side effects.
- The study highlights the successful application of Lu-DOTATATE in treating two pediatric patients with metastatic NET, suggesting potential benefits for young patients.
Article Abstract
Neuroendocrine tumors (NETs) of the pancreas and midgut are extremely rare in children, and patients presenting with metastatic disease have poor survival. Given this rarity, treatments are extrapolated from guidelines for adults with NET. Recent clinical trials in adults with NETs have shown that the addition of peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE resulted in a disease control rate of nearly 80%, with minimal side effects. We report our experience using Lu-DOTATATE to treat two pediatric patients with metastatic NET.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.29056 | DOI Listing |
Publication Analysis
Top Keywords
peptide receptor
8
receptor radionuclide
8
radionuclide therapy
8
neuroendocrine tumors
8
therapy treatment
4
treatment metastatic
4
metastatic neuroendocrine
4
tumors children
4
children neuroendocrine
4
tumors nets
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!